BioCentury | Aug 21, 2019
Distillery Therapeutics

LGALS3 identified as Huntington disease target

...plaque psoriasis, melanoma and liver and pulmonary fibrosis. Galecto Biotech AB has the LGALS3 inhibitor TD139...
BioCentury | Mar 9, 2019
Finance

Seventure maps its microbiome future

...C round for Galecto Biotech AB through the new fund. While the company's lead candidate TD139...
BioCentury | Nov 2, 2018
Financial News

Galecto raises €79M to advance pipeline of galectin inhibitors

...months, Galecto plans to begin a Phase II/III trial of its lead galectin-3 (LGALS3) inhibitor, TD139...
...expected to provide runway through 2021, when the company plans to submit an NDA for TD139...
BioCentury | Oct 26, 2018
Financial News

Galecto raises €79M to advance pipeline of galectin inhibitors

...months, Galecto plans to begin a Phase II/III trial of its lead galectin-3 (LGALS3) inhibitor, TD139...
...expected to provide runway through 2021, when the company plans to submit an NDA for TD139...
...OrbiMed's Chau Khuong, HBM's Chandra Leo and OrbiMed Israel's Erez Chimovits joined Galecto's board. Elizabeth S. Eaton TD139 Galecto...
BioCentury | Mar 17, 2017
Clinical News

TD139: Ph IIa data

...Phase IIa portion of a double-blind, placebo-controlled, U.K. Phase Ib/IIa trial showed that once-daily inhaled TD139...
...study" slated to start in the "near future." Galecto Biotech AB , Copenhagen, Denmark Product: TD139...
...alveolar macrophage concentration of TD139 Status: Phase IIa data Milestone: Additional Phase IIa data (5/2017) Chris Lieu TD139 Galecto...
BioCentury | Nov 19, 2016
Strategy

Adding on in fibrosis

...one in IPF and one in myelofibrosis. Data from both are expected next year. Galecto’s TD139...
...an inhaled galectin-3 (LGALS3) inhibitor that is in a Phase I/II trial to treat IPF. TD139...
...across fibrotic indications because of its local delivery to the lung. Burgess didn’t comment on TD139’s...
BioCentury | Oct 15, 2015
Finance

Public-Private Partnership Roundup

...a dual CCR2 / CCR5 antagonist for diabetic kidney disease, and Galecto Biotech AB 's TD139...
BioCentury | Sep 1, 2015
Company News

BMS gets option to buy fibrosis company Promedior

...also holds an exclusive option to acquire Galecto Biotech AB (Copenhagen, Denmark), which is developing TD139...
BioCentury | Mar 2, 2015
Clinical News

TD139: Phase Ib data

...double-blind, placebo-controlled, U.K. Phase Ib/IIa trial showed that single ascending doses of 0.15-50 mg inhaled TD139...
...pulmonary fibrosis (IPF) in the Phase IIa portion to evaluate ascending doses of once-daily inhaled TD139...
...in May and Phase IIa data in 3Q16. Galecto Biotech AB , Copenhagen, Denmark Product: TD139...
BioCentury | Nov 10, 2014
Company News

Galecto, Bristol-Myers deal

...Galecto Biotech granted Bristol-Myers Squibb an exclusive option to acquire the biotech. Galecto's TD139 , an...
...option no later than 60 days after the completion of the Phase Ib trial of TD139...
Items per page:
1 - 10 of 18